Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN).

被引:5
|
作者
Beltran, Himisha
Dowlati, Afshin
Jain, Prantesh
Johnson, Melissa Lynne
Sanborn, Rachel E.
Thompson, Jonathan Robert
Mamdani, Hirva
Schenk, Erin L.
Aggarwal, Rahul Raj
Sankar, Kamya
Gramza, Ann W.
Anand, Banmeet S.
Choudhury, Noura J.
机构
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Case Western Reserve Univ, Univ Hosp Siedman Canc Ctr, Cleveland, OH USA
[3] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Earle A Chiles Res Inst, Portland, OR USA
[6] Froedtert, Milwaukee, WI USA
[7] Med Coll Wisconsin, Workforce Hlth, Milwaukee, WI USA
[8] Barbara Ann Karmanos Canc Inst, Detroit, MI USA
[9] Univ Colorado Anschutz Med Campus, Aurora, CO USA
[10] Univ Calif San Francisco, San Francisco, CA USA
[11] Cedars Sinai Med Ctr, Los Angeles, CA USA
[12] Harpoon Therapeut Inc, South San Francisco, CA USA
[13] Mem Sloan Kettering Canc Ctr, New York, NY USA
关键词
261-492-199-2823-7422-11198; 283-197-6219; 613-225-2577-2545; 283-183-138-226; 261-492-199-2823; 613-615-646-4685-2424; 613-225-2782; 6; 4; 3; 38092-34755; 38092-21757; 38092-21759; 5; 2; 1;
D O I
10.1200/JCO.2024.42.4_suppl.121
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:121 / 121
页数:1
相关论文
共 36 条
  • [21] A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE®) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction cancer
    Lordick, F.
    Buxo Orra, E.
    Cervantes, A.
    Dayyani, F.
    Rocha-Lima, C.
    Greil, R.
    van Laarhoven, H.
    Lorenzen, S.
    Kischel, R.
    Shitara, K.
    Chao, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S114 - S114
  • [22] Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC).
    Owonikoko, Taofeek K.
    Champiat, Stephane
    Johnson, Melissa Lynne
    Govindan, Ramaswamy
    Izumi, Hiroki
    Lai, W. Victoria Victoria
    Borghaei, Hossein
    Boyer, Michael J.
    Boosman, Rene J.
    Hummel, Horst-Dieter
    Blackhall, Fiona Helen
    Reguart, Noemi
    Dowlati, Afshin
    Zhang, Yiran
    Mukherjee, Sujoy
    Minocha, Mukul
    Zhou, Yanchen
    Shetty, Aditya
    Sadraei, Nooshin Hashemi
    Paz-Ares, Luis G.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Ben Tran
    Horvath, Lisa
    Rettig, Matthew
    Fizazi, Karim
    Lolkema, Martijn P.
    Dorff, Tanya B.
    Greil, Richard
    Machiels, Jean-Pascal H.
    Autio, Karen A.
    Rottey, Sylvie
    Adra, Nabil
    Garje, Rohan
    Roncolato, Felicia
    Tagawa, Scott T.
    Shariat, Shahrokh F.
    Salvati, Mark
    Poon, Shirley
    Kouros-Mehr, Hosein
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] Phase I study of AMG 757, a delta-like ligand 3 (DLL3) targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer (SCLC)
    Paz-Ares, L.
    Owonikoko, T. K.
    Johnson, M.
    Govindan, R.
    Izumi, H.
    Lai, V.
    Borghaei, H.
    Boyer, M.
    Boosman, R. J.
    Hummel, H-D.
    Blackhall, F.
    Dowlati, A.
    Zhang, Y.
    Mukherjee, S.
    Sable, B.
    Pati, A.
    Shetty, A.
    Sadraei, N. Hashemi
    Champiat, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S720 - S721
  • [25] DeLLphi-303: Phase Ib first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE®), with carboplatin, etoposide, and PD-L1 inhibition in extensive stage small cell lung cancer (ES-SCLC)
    Gadgeel, S. M.
    Al-Mondhiry, J.
    Ahn, M-J.
    Kim, S-W.
    Paz-Ares, L.
    Prenen, H.
    Boyer, M.
    Bustamante Alvarez, J. G.
    Solomon, B.
    Huang, S.
    Minocha, M.
    Kistler, M.
    Sadraei, N. Hashemi
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1255 - S1255
  • [26] Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Tran, Ben
    Horvath, Lisa
    Dorff, Tanya B.
    Greil, Richard
    Machiels, Jean-Pascal H.
    Roncolato, Felicia
    Autio, Karen A.
    Rettig, Matthew
    Fizazi, Karim
    Lolkema, Martijn P.
    Fermin, Anthony C.
    Salvati, Mark
    Kouros-Mehr, Hosein
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [27] Phase II study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE®) immuno-oncology therapy targeting DLL3, in third-line or later small cell lung cancer (SCLC)
    Ramalingam, S. S.
    Ahn, M-J.
    Akamatsu, H.
    Blackhall, F.
    Borghaei, H.
    Hummel, H-D.
    Johnson, M.
    Reck, M.
    Zhang, Y.
    Jandial, D.
    Cheng, S.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2022, 33 : S103 - S104
  • [28] A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Tran, B.
    Kouros-Mehr, H.
    Fermin, A.
    Horvath, L.
    Roncolato, F.
    Rettig, M.
    Dorff, T.
    Tagawa, S. T.
    Subudhi, S. K.
    Antonarakis, E. S.
    Armstrong, A. J.
    Petrylak, D. P.
    Fizazi, K.
    Salvati, M. E.
    Scher, H. I.
    ANNALS OF ONCOLOGY, 2019, 30 : 353 - 353
  • [29] Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)
    Tran, B.
    Horvath, L.
    Dorff, T.
    Rettig, M.
    Lolkema, M. P.
    Machiels, J-P.
    Rottey, S.
    Autio, K.
    Greil, R.
    Adra, N.
    Lemech, C.
    Minocha, M.
    Cheng, F-C.
    Kouros-Mehr, H.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S507 - S507
  • [30] Preliminary phase I results from a first-in-human study of ZG006, a trispecific anti-T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with advanced small cell lung cancer or neuroendocrine carcinoma
    Wang, Q.
    Chai, X.
    Lin, R.
    Zheng, L.
    Cao, D.
    Qu, X.
    Liu, L.
    Wu, L.
    Mou, H.
    Xu, Q.
    Shi, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S532 - S533